Top

Taking a novel approach to drug development

Clinical Trials

Lantern Pharma is recruiting for two Phase 2 clinical trials:
1) LP-100 for AR-targeted and Docetaxel-Pretreated mCRPC Patients 2) LP-300 for Never-Smokers with NSCLC Adenocarcinoma

See more information below.

The Harmonic™ Clinical Trial is enrolling participants in a Phase 2 multi-center study to evaluate an investigational new drug called LP-300.

This trial is for never smokers with relapsed advanced primary adenocarcinoma of the lung, which is a type of non-small cell lung cancer (NSCLC).

LP-300 for Never-smokers with NSCLC Adenocarcinoma 

STAGE

Phase 2

DISEASE

Non-Small Cell Lung Cancer

TREATMENT

LP-300 + Carboplatin and Pemetrexed

LOCATION OF TRIAL

Multiple Sites

ClinicalTrials.gov ID

NCT05456256

The FDA has authorized the launch of our Phase 2 clinical trial (the “Harmonic™ Trial”) of LP-300 in combination with carboplatin and pemetrexed in never smoker patients with relapsed advanced primary adenocarcinoma of the lung after treatment with tyrosine kinase inhibitors. Our purpose in conducting the study is to determine the potential clinical advantages for this drug combination in the study-defined patient population. 

The trial is designed as a multicenter, open label, Phase 2 trial with planned enrollment of approximately 90 patients. Patients who are never smokers with lung adenocarcinoma and have relapsed after prior treatment with tyrosine kinase inhibitors will be eligible for enrollment. Following a six-patient safety lead-in stage, the trial will consist of randomization in a 2:1 allocation ratio to one of two arms: Arm A (consisting of carboplatin, pemetrexed, and LP-300) or Arm B (consisting of carboplatin and pemetrexed).

For more information on the Harmonic™ clinical trial, please visit www.harmonictrial.com or the ClinicalTrials.gov study page.

LP-100 for AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

STAGE

Phase 2

DISEASE

Metastatic Castration-Resistant Prostate Cancer

TREATMENT

Irofulven + Prednisolone 10mg

LOCATION OF TRIAL

Rigshospitalet, Dept. of Oncology
Copenhagen, Denmark, 2100

ClinicalTrials.gov ID

NCT03643107

This study seeks to evaluate the anti-tumor effect after treatment of Irofulven (LP-100) in combination with prednisolone in patients who progressed on androgen receptor(AR)-targeted therapy and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients. A drug response predictor (DRP®) biomarker in prostate cancer patients will identify patients likely to respond to and benefit from treatment with Irofulven.

For more information on the ongoing Phase 2 study of Irofulven in patients with mCRPC, please visit the
study page.

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.